Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Lecanemab and what this means for the future treatment of Alzheimer’s disease

Jesse Cedarbaum, MD, FAAN, FANA, Yale University School of Medicine, New Haven, CT & Coeruleus Clinical Sciences LLC, Woodbridge, CT, shares his perspectives on the drug lecanemab and the future therapeutic directions for Alzheimer’s disease (AD). Prof. Cedarbaum expresses that although the results from the recent Clarity AD clinical trial (NCT03887455) testing the safety and efficacy of lecanemab are very positive, the drug still only slowed the progression of AD by about 27%, meaning that there is lots of room for improvements in order to stop the progression of AD altogether. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.